Cirrhosis – Pipeline Review, 2019

Cirrhosis refers to a medical condition which occurs in the liver, which causes the gradual replacement of healthy liver cells by scar tissue in individuals. Cirrhosis generally occurs over a long period of time and can be attributed to infections and alcohol addiction. In most of the instances, the damage to the liver cannot be reversed, but if diagnosed early there are numerous treatment options that can keep the associated problems in check. Cirrhosis occurs when the liver is repeated damaged, leading it to cause tough scar tissue and due to the buildup of the scar tissue, the liver no longer functions properly.

Some of the common symptoms associated with cirrhosis include fatigue and weakness, weight loss, lack of appetite and nausea. One of the most common diagnostic methods for cirrhosis includes the conduction of a blood test, so the cirrhosis can be diagnosed at a certain stage. Some of the treatment options for cirrhosis include lifestyle changes such as a low sodium diet and complete stoppage of alcohol consumption, medications and in advanced stages, liver transplantation. Some of the medications for the cirrhosis include blood pressure medications, vitamins, antibiotics, and vaccinations.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for cirrhosis. For instance; BMS-986036, which is being studied by Bristol-Myers Squibb Company, is currently in phase-2 clinical trials for a study of BMS-986036 in subjects with non-alcoholic steatohepatitis (NASH).

At present, around 60% of the pipeline candidates for cirrhosis are in the phase-2 and phase-3 stage combined. Majority of the studies are sponsored by industry.

Report Description

The report on ‘Cirrhosis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Cirrhosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Cirrhosis.

The report on ‘Cirrhosis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Cirrhosis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Cirrhosis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary